公开(公告)号：US20240383960A1

公开(公告)日：2024-11-21

申请号：US18777223

申请日：2024-07-18

Applicant: Carmot Therapeutics Inc.

Inventor： Daniel Erlanson ,  Raymond V. Fucini ,  Stig Hansen ,  Jeff Iwig ,  Shyam Krishnan ,  Enrique Moya ,  Steven Sethofer

IPC: C07K14/605 ,  A61K38/00

Abstract: This disclosure features chemical entities (e.g., a compound or a pharmaceutically acceptable salt) that modulate (e.g., agonize or partially agonize or antagonize) glucagon-like peptide-1 receptor (“GLP-1R”) and/or the gastric inhibitory polypeptide receptor (“GIPR”). The chemical entities are useful, e.g., for treating a disease, disorder, or condition in which modulation (e.g., agonism, partial agonism or antagonism) of GLP-1R and/or GIPR activities is beneficial for the treatment or prevention of the underlying pathology and/or symptoms and/or progression of the disease, disorder, or condition. In some embodiments, modulation results in enhancement of (e.g., increases) existing levels (e.g., normal or below normal levels) of GLP-1R and/or GIPR activity (e.g., signaling). In some embodiments, the chemical entities described herein further modulate (e.g., attenuate, uncouple) □-arrestin signaling relative to what is observed with the native ligand. This disclosure also features compositions as well as other methods of using and making the said chemical entities.

公开(公告)号：US20230151074A1

公开(公告)日：2023-05-18

申请号：US17744540

申请日：2022-05-13

Applicant: Carmot Therapeutics, Inc.

Inventor： Daniel Erlanson ,  Raymond V. Fucini ,  Stig Hansen ,  Jeff Iwig ,  Shyam Krishnan ,  Enrique Moya ,  Steven Sethofer

IPC: C07K14/605

CPC classification number: C07K14/605 ,  A61K38/00

Abstract: This disclosure features chemical entities (e.g., a compound or a pharmaceutically acceptable salt) that modulate (e.g., agonize or partially agonize or antagonize) glucagon-like peptide-1 receptor (“GLP-1R”) and/or the gastric inhibitory polypeptide receptor (“GIPR”). The chemical entities are useful, e.g., for treating a disease, disorder, or condition in which modulation (e.g., agonism, partial agonism or antagonism) of GLP-1R and/or GIPR activities is beneficial for the treatment or prevention of the underlying pathology and/or symptoms and/or progression of the disease, disorder, or condition. In some embodiments, modulation results in enhancement of (e.g., increases) existing levels (e.g., normal or below normal levels) of GLP-1R and/or GIPR activity (e.g., signaling). In some embodiments, the chemical entities described herein further modulate (e.g., attenuate, uncouple) β-arrestin signaling relative to what is observed with the native ligand. This disclosure also features compositions as well as other methods of using and making the said chemical entities.